Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03498027 · ClinicalTrials.gov registry record
Febrile Whole Blood Specimen Collection and Testing
A clinical trial of Anthrax and Febrile Infection, sponsored by MRI Global.
- Completed
- Registry status
- 97
- Enrollment target
- 3
- Study locations
NCT03498027: Completed study of Anthrax and Febrile Infection, sponsored by MRI Global.
NCT03498027 is a study of Anthrax and Febrile Infection that has completed, run by MRI Global. The registered enrollment target is 97 participants, below the 762-participant average among 6 other Anthrax trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03498027, a study of Anthrax and Febrile Infection, has completed, sponsored by MRI Global.
- COMPLETED
- Registry status
- 97 participants
- Enrollment target
- 3
- Study locations
Study Summary
Whole blood samples will be collected from febrile patients presenting with fever of unknown origin and flu-like syndromes. Collection sites will consent patients and collect one (1) 4 mL whole blood sample from adults and either (1) 2 mL pediatric whole blood sample or 0.5 mL whole blood sample collected in a micro collection container from pediatric patients from each patient enrolled into the study. Study site will test whole blood samples received from collection sites daily using the Applied Biosystems™ Bacillus anthracis Detection Kit. Data generated will demonstrate product specificity when testing febrile whole blood samples.
Primary Outcome
Data generated will demonstrate product specificity when testing whole blood samples.
Conditions Studied
Interventions
- DEVICE TaqMan Bacillus anthracis Detection Kit
Study Locations (3)
Massachusetts
- New England Center for Clinical Research - Fall River
- Medical Research Network - Franklin
Florida
- Boca Biolistics - Tarpon Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2018-07-26 |
| Est. Completion | 2018-10-18 |
What the finished NCT03498027 record still lists
NCT03498027 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 762-participant average among 6 other Anthrax trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Anthrax appearing as the primary indexed condition, and to 1 intervention - of which TaqMan Bacillus anthracis Detection Kit is the first listed.
NCT03498027 reports a single indexed study location in Massachusetts, Florida.
Frequently Asked Questions
What is clinical trial NCT03498027 about?
NCT03498027 is a clinical study titled "Febrile Whole Blood Specimen Collection and Testing". Whole blood samples will be collected from febrile patients presenting with fever of unknown origin and flu-like syndromes. Collection sites will consent patients and collect one (1) 4 mL whole blood sample from adults and either (1) 2 mL pediatric whole blood sample or 0.5 mL whole blood sample col...
What is the current status of trial NCT03498027?
This trial is currently completed. The enrollment target is 97 participants. The study started on 2018-07-26. Estimated completion is 2018-10-18.
What conditions does trial NCT03498027 study?
This clinical trial studies the following conditions: Anthrax, Febrile Infection.
What interventions are being tested in trial NCT03498027?
The interventions under investigation include: TaqMan Bacillus anthracis Detection Kit (DEVICE).
Who is sponsoring clinical trial NCT03498027?
This trial is sponsored by MRI Global, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03498027 being conducted?
This trial has 3 study locations across Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anthrax
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
RECRUITING
-
Anthrax AV7909 Boost Evaluation Study
ACTIVE NOT RECRUITING · Phase 2
-
VELOCITY: An Anthrax Vaccine Clinical Study
COMPLETED · Phase 3
-
PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine
COMPLETED · Phase 1
-
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
COMPLETED · Phase 2
-
Anthrax Vaccine Clinical Trials
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI